Full access
Clinical & Research News
Published Online: 2 September 2005

FDA Official Comments on Data

Publication: Psychiatric News
Volume 40, Number 17
https://doi.org/10.1176/pn.40.17.00400039
Track CitationsAdd to favorites
Thomas Laughren, M.D., acting director of the FDA Division of Psychiatry Products within the Center for Drug Evaluation and Research, told Psychiatric News via e-mail that despite formal requests from both APA and the AMA, the FDA “has not systematically tracked antidepressant prescribing in the pediatric population since” the black box was added to the labels of all antidepressants marketed in the U.S.
Psychiatric News asked Laughren to comment on the data from NDC Health on antidepressant prescriptions and what impact—if any—the data might have on the FDA's efforts to label antidepressants appropriately.
“For the sake of argument,” Laughren responded, “let's assume that the NDC Health data do accurately reflect a decline in antidepressant prescribing in the pediatric age group. There would be no easy interpretation of such a finding, in isolation.
“A decline in prescribing might be an indication of a decrease in access to these medications for patients who may benefit, but alternatively, it could be a reflection of more rational prescribing that is consistent with a more appropriate risk-benefit model.
“Even tracking suicidal behavior in this population is not a failsafe approach to assessing the impact of this labeling change, because secular trends in such behavior are influenced by many different factors.
“Labeling language is of course a dynamic process that is subject to change in the face of new knowledge. However, we feel that the type of data most likely to have an impact on future changes of the labeling language with regard to suicidality would be systematically collected data that better define the risks and benefits of these drugs in the pediatric population than have the studies done to date.”
Laughren closed his e-mail by stating, “It is possible that other sources of evidence could have an impact on the FDA's thinking about appropriate prescribing of antidepressants in the pediatric population.”

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 40 • Number 17 • September 2, 2005
Pages: 39

History

Published online: 2 September 2005
Published in print: September 2, 2005

Authors

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

View Options

View options

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.